Olmeamlodipinhct Puren (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide, the active ingredient in Olmeamlodipinhct Puren, is a combination antihypertensive presented as a tablet for oral use. It treats hypertension in adults, often when single‑agent therapy is insufficient. GNH USA supplies Olmeamlodipinhct Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmeamlodipinhct Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmeamlodipinhct Puren is a combination antihypertensive used to manage high blood pressure and related cardiovascular risk factors. - Hypertension: lowers systolic and diastolic blood pressure to reduce risk of stroke and heart attack. - Hypertensive heart disease: improves cardiac workload and prevents disease progression. - Chronic kidney disease with hypertension: slows renal function decline by controlling blood pressure.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Peripheral edema - Headache - Flushing - Fatigue - Increased urination

Serious or Rare Side Effects: - Severe hypotension - Electrolyte disturbances (e.g., low potassium) - Acute kidney injury - Angio‑edema - Liver enzyme elevation - Severe skin reactions such as Stevens‑Johnson syndrome

When prescribing Olmeamlodipinhct Puren, clinicians should consider several safety aspects. - Renal function: assess baseline creatinine and monitor periodically. - Electrolytes: check serum potassium and sodium before initiation and during therapy. - Cardiovascular status: avoid rapid blood‑pressure fall in patients with aortic stenosis. - Pregnancy: contraindicated in the second and third trimesters. - Drug hypersensitivity: discontinue if angio‑edema or severe rash develops. - Store at below 25°C: keep in the original container, protect from moisture and light.

Olmeamlodipinhct Puren can interact with several medicines, requiring clinical vigilance.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of hyperkalaemia and renal impairment. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase amlodipine levels.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - Lithium: may increase lithium concentrations. - Diuretics other than hydrochlorothiazide: additive electrolyte disturbances. - Antidiabetic agents: enhanced glucose‑lowering effect may require dose adjustment.